Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Cyst Fibros. 2019 Sep;18(5):700-707. doi: 10.1016/j.jcf.2019.04.014. Epub 2019 May 3.

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.

Author information

1
Department of Thoracic Medicine, The Prince Charles Hospital and QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: scott.bell@health.qld.gov.au.
2
Manchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Manchester, UK.
3
University Hospital Gasthuisberg, Leuven, Belgium.
4
Department of Medical Microbiology, Charles University, Motol University Hospital, Prague, Czech Republic.
5
Queen's University, Belfast, UK.
6
University College Cork, Cork, Ireland.
7
Mother and Child Health Institute of Serbia, Belgrade, Serbia.
8
Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
9
Antwerp University Hospital, Edegem, Belgium.
10
Galapagos NV, Mechelen, Belgium.
11
Galapagos UBV, Leiden, the Netherlands.
12
AbbVie Inc., North Chicago, IL, USA.
13
UMC Utrecht, Utrecht, the Netherlands.

Abstract

BACKGROUND:

Several treatment approaches in cystic fibrosis (CF) aim to correct CF transmembrane conductance regulator (CFTR) function; the efficacy of each approach is dependent on the mutation(s) present. A need remains for more effective treatments to correct functional deficits caused by the F508del mutation.

METHODS:

Two placebo-controlled, phase 2a studies evaluated GLPG2222, given orally once daily for 29 days, in subjects homozygous for F508del (FLAMINGO) or heterozygous for F508del and a gating mutation, receiving ivacaftor (ALBATROSS). The primary objective of both studies was to assess safety and tolerability. Secondary objectives included assessment of pharmacokinetics, and of the effect of GLPG2222 on sweat chloride concentrations, pulmonary function and respiratory symptoms.

RESULTS:

Fifty-nine and 37 subjects were enrolled into FLAMINGO and ALBATROSS, respectively. Treatment-related treatment-emergent adverse events (TEAEs) were reported by 29.2% (14/48) of subjects in FLAMINGO and 40.0% (12/30) in ALBATROSS; most were mild to moderate in severity and comprised primarily respiratory, gastrointestinal, and infection events. There were no deaths or discontinuations due to TEAEs. Dose-dependent decreases in sweat chloride concentrations were seen in GLPG2222-treated subjects (maximum decrease in FLAMINGO: -17.6 mmol/L [GLPG2222 200 mg], p < 0.0001; ALBATROSS: -7.4 mmol/L [GLPG2222 300 mg], p < 0.05). No significant effects on pulmonary function or respiratory symptoms were reported. Plasma GLPG2222 concentrations in CF subjects were consistent with previous studies in healthy volunteers and CF subjects.

CONCLUSIONS:

GLPG2222 was well tolerated. Sweat chloride reductions support on-target enhancement of CFTR activity in subjects with F508del mutation(s). Significant improvements in clinical endpoints were not demonstrated. Observed safety results support further evaluation of GLPG2222, including in combination with other CFTR modulators.

FUNDING:

Galapagos NV. Clinical trial registration numbers FLAMINGO, NCT03119649; ALBATROSS, NCT03045523.

KEYWORDS:

CFTR modulator; Cystic fibrosis; F508del; GLPG2222; Gating mutation; Ivacaftor

PMID:
31056441
DOI:
10.1016/j.jcf.2019.04.014
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center